Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eluxadoline in Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)
NCT03339128Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2017
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of eluxadoline in Irritable bowel syndrome with diarrhea (IBS-D), sponsored by AbbVie Inc.. Started Nov 2017; status: completed.
02
Drugs
eluxadoline
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT03339128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03339128.